Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients with High-Risk Stage II Colorectal Cancer

Timothy J. Iveson, Alberto F. Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang Shu Ou, Jeffrey P. Meyers, Qian Shi, Axel Grothey, Mark P. Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels H. Hollander, Fabio Galli, Kentaro Yamazaki, Vassilis Georgoulias, Rachel Kerr, Eiji Oki, Sara Lonardi, Andrea HarkinGerardo Rosati, James Paul

研究成果: ジャーナルへの寄稿学術誌査読

61 被引用数 (Scopus)


PURPOSE:As oxaliplatin results in cumulative neurotoxicity, reducing treatment duration without loss of efficacy would benefit patients and healthcare providers.PATIENTS AND METHODS:Four of the six studies in the International Duration of Adjuvant Chemotherapy (IDEA) collaboration included patients with high-risk stage II colon and rectal cancers. Patients were treated (clinician and/or patient choice) with either fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX) and randomly assigned to receive 3- or 6-month treatment. The primary end point is disease-free survival (DFS), and noninferiority of 3-month treatment was defined as a hazard ratio (HR) of < 1.2- v 6-month arm. To detect this with 80% power at a one-sided type one error rate of 0.10, a total of 542 DFS events were required.RESULTS:3,273 eligible patients were randomly assigned to either 3- or 6-month treatment with 62% receiving CAPOX and 38% FOLFOX. There were 553 DFS events. Five-year DFS was 80.7% and 83.9% for 3-month and 6-month treatment, respectively (HR, 1.17; 80% CI, 1.05 to 1.31; P [for noninferiority].39). This crossed the noninferiority limit of 1.2. As in the IDEA stage III analysis, the duration effect appeared dependent on the chemotherapy regimen although a test of interaction was negative. HR for CAPOX was 1.02 (80% CI, 0.88 to 1.17), and HR for FOLFOX was 1.41 (80% CI, 1.18 to 1.68).CONCLUSION:Although noninferiority has not been demonstrated in the overall population, the convenience, reduced toxicity, and cost of 3-month adjuvant CAPOX suggest it as a potential option for high-risk stage II colon cancer if oxaliplatin-based chemotherapy is suitable. The relative contribution of the factors used to define high-risk stage II disease needs better understanding.

ジャーナルJournal of Clinical Oncology
出版ステータス出版済み - 2月 20 2021

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究


「Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients with High-Risk Stage II Colorectal Cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。